Literature DB >> 8543811

Quantitative analysis of the expression of the HLA-DRB genes at the transcriptional level by competitive polymerase chain reaction.

R Vincent1, P Louis, C Gongora, I Papa, J Clot, J F Eliaou.   

Abstract

In addition to polymorphism of the peptide-binding site, the density of the MHC class II molecules expressed on the membrane of APC could well play a significant role in the MHC-peptide-TCR interaction during the immune response. We therefore investigated the regulation of the expression of the HLA-DRB genes at the transcriptional level. A competitive PCR approach was used to estimate the quantities of the HLA-DRB transcripts in peripheral blood B cells. When comparing the amounts of steady-state mRNAs among the different DRB1 alleles, the DRB1 transcripts in the DR52 haplotype group were found to be 2.5 to 3.5 times more abundant than the DRB1*01 transcripts, 1.5 to 2 times more abundant than the DRB1*04 transcripts, and 7 times more abundant than the DRB1*08 transcripts. Within the DR52 haplotype group, the DRB1 and DRB3 transcripts had the same abundance. Taken together, these results are in good agreement with the previously reported transcriptional activities of the DRB promoters except for DRB1*04, thus suggesting a differential post-transcriptional regulation among the DRB1 mRNAs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8543811

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  HLA-A and HLA-B transcription decrease with ageing in peripheral blood leucocytes.

Authors:  C Le Morvan; M Cogné; M Drouet
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

2.  HLA-DRB1 gene transcripts in rheumatoid arthritis.

Authors:  S Kerlan-Candon; B Combe; R Vincent; J Clot; V Pinet; J F Eliaou
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

3.  The chicken BF1 (classical MHC class I) gene shows evidence of selection for diversity in expression and in promoter and signal peptide regions.

Authors:  Ann Marie O'Neill; Emily J Livant; Sandra J Ewald
Journal:  Immunogenetics       Date:  2009-02-11       Impact factor: 2.846

4.  Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation.

Authors:  Rosa Faner; Eddie James; Laurie Huston; Ricardo Pujol-Borrel; William W Kwok; Manel Juan
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

5.  Constitutive expression of interleukin-18 and interleukin-18 receptor mRNA in tumour derived human B-cell lines.

Authors:  S L Lorey; Y C Huang; V Sharma
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

6.  Patterned variation in murine MHC promoters.

Authors:  N Avrion Mitchison; Jurgen Roes
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-19       Impact factor: 11.205

7.  Differential expression of major histocompatibility complex class II genes on murine macrophages associated with T cell cytokine profile and protective/suppressive effects.

Authors:  M Baumgart; V Moos; D Schuhbauer; B Müller
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

Review 8.  Regulation of major histocompatibility complex class II gene expression, genetic variation and disease.

Authors:  L Handunnetthi; S V Ramagopalan; G C Ebers; J C Knight
Journal:  Genes Immun       Date:  2009-11-05       Impact factor: 2.676

9.  Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations.

Authors:  Antonio Alcina; María Del Mar Abad-Grau; María Fedetz; Guillermo Izquierdo; Miguel Lucas; Oscar Fernández; Dorothy Ndagire; Antonio Catalá-Rabasa; Agustín Ruiz; Javier Gayán; Concepción Delgado; Carmen Arnal; Fuencisla Matesanz
Journal:  PLoS One       Date:  2012-01-13       Impact factor: 3.240

10.  Interaction between Treg apoptosis pathways, Treg function and HLA risk evolves during type 1 diabetes pathogenesis.

Authors:  Sanja Glisic; Parthav Jailwala
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.